Irradiation and stem cells used in new treatment to enable kidney recipients to forego immunosuppressant drugs

March 8, 2012 By Bruce Goldman, Stanford University Medical Center

With a novel approach that creates a more-accepting immune system, Stanford School of Medicine physicians have pioneered a technique that frees kidney-transplant recipients from a life on anti-rejection drugs.

Unlike the standard care after such a transplant, the Stanford doctors irradiate a patient’s lymph nodes, spleen and thymus in a carefully targeted manner, thus temporarily weakening the patient’s immune system; then they administer drawn from the kidney donor’s blood to rebuild an immune system that is more tolerant of the donated kidney.

While anti-rejection drugs have been standard fare for transplant patients — they ward off of a transplanted organ by the recipient’s immune system — they carry their own risk of serious side effects, such as high blood pressure, diabetes and cancer. They also can be somewhat toxic to the kidneys. What’s more, they don’t always work. In those cases, the patient experiences a gradual deterioration of the donated organ until it eventually fails, necessitating another transplant operation or a return to dialysis.

The new protocol, developed by Samuel Strober, MD, professor of medicine, could banish such worries. The combination of targeted radiation and the organ donor’s blood-forming stem cells — along with antibodies that selectively deplete some of the recipient’s immune cells — suppresses immune activity that would otherwise destroy the donated kidney. The new donor cells differentiate to join the components of the recipient’s own , which eventually returns to its pre-transplant state of readiness but now tolerates the new organ. “It casts a blind eye on the foreign tissue of the graft,” according to Strober.

Under the protocol, kidney recipients receive radiation treatment and injections of antibodies while still in the hospital, a few days after surgery, and additional radiation doses over the next several days on an outpatient basis. About 10 days post-surgery, recipients get an injection of cells taken from the organ donor. All patients initially are put on two of the same immune-suppressing drugs (plus antivirals and antibiotics) that transplantation patients would normally get.

After a month, one of the drugs is withdrawn; thereafter, Strober and his colleagues continually monitor numerous parameters including the mixing of donor and recipient immune cells. If that mixing seems in balance six to 12 months after surgery, the recipient’s second immunosuppressant-drug dose is discontinued.

The new protocol could spell substantial savings to the health-care system. While it carries a total expense estimated to range from $20,000 and $40,000, it has the potential to pay for itself within a few years by eliminating the $12,000 to $15,000 annual expense for anti-rejection drugs, without adding any extra hospital time. And it also could prevent failure of a transplanted kidney, which comes with an approximately $80,000 price tag to the health-care system during the year when the failure occurs.

Explore further: New Stanford regimen frees kidney-transplant patients from dependency on immunosuppresant drugs

Related Stories

New Stanford regimen frees kidney-transplant patients from dependency on immunosuppresant drugs

October 5, 2011
Investigators at the Stanford University School of Medicine have developed a novel protocol that allows kidney-transplant recipients to jettison their indispensable immune-suppressing drugs. The protocol could also spell ...

New transplant method may allow kidney recipients to live life free of anti-rejection medication

March 7, 2012
New ongoing research published today in the journal Science Translational Medicine suggests organ transplant recipients may not require anti-rejection medication in the future thanks to the power of stem cells, which may ...

'Stimulated' stem cells stop donor organ rejection

October 18, 2011
(Medical Xpress) -- Johns Hopkins researchers have developed a way to stimulate a rat’s stem cells after a liver transplant as a means of preventing rejection of the new organ without the need for lifelong immunosuppressant ...

Recommended for you

Genomics reveals key macrophages' involvement in systemic sclerosis

January 18, 2018
A new international study has made an important discovery about the key role of macrophages, a type of immune cell, in systemic sclerosis (SSc), a chronic autoimmune disease which currently has no cure.

First vaccine developed against grass pollen allergy

January 18, 2018
Around 400 million people worldwide suffer in some form or other from a grass pollen allergy (rhinitis), with the usual symptoms of runny nose, cough and severe breathing problems. In collaboration with the Viennese firm ...

Researchers discover key driver of atopic dermatitis

January 17, 2018
Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction. In their latest study, researchers at La Jolla Institute reveal an important player that promotes ...

Who might benefit from immunotherapy? New study suggests possible marker

January 16, 2018
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments.

Researchers identify new way to unmask melanoma cells to the immune system

January 16, 2018
system, which enables these deadly skin cancers to grow and spread.

How the immune system's key organ regenerates itself

January 15, 2018
With advances in cancer immunotherapy splashing across headlines, the immune system's powerful cancer assassins—T cells—have become dinner-table conversation. But hiding in plain sight behind that "T" is the organ from ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.